Edward Dyson

Ed counsels public issuers, emerging companies, entrepreneurs, institutional investors and investment banks on a comprehensive range of corporate and capital markets transactions.

• 取扱案件

  Capital Markets & Public Equity

  Acting for issuer:

  • AccuStem Sciences Inc. on demerger from its London Stock Exchange Main Market-listed parent and subsequent US OTC listing.
  • Ananda Pharma plc on secondary US OTCQB Venture Market listing.
  • Attica Bank S.A. on Athens Stock Exchange follow-on equity offerings.
  • Autolus Therapeutics plc on Nasdaq IPO.
  • B&M European Value Retail S.A. (B&M Stores) on London Stock Exchange Main Market IPO.
  • capAI plc on London Stock Exchange Main Market stock loan, substantial property transaction, and related-party transactions.
  • Castillo Copper Limited on dual-listed ASX and London Stock Exchange Main Market follow-on offerings.
  • Cobra Resources plc on London Stock Exchange Main Market follow-on offerings.
  • Codex Acquisitions plc on London Stock Exchange Main Market SPAC IPO.
  • Endava plc on NYSE IPO.
  • e-Therapeutics plc on secondary US OTCQX market listing.
  • Farmacosmo S.p.A. on Euronext Growth Milan IPO.
  • GEM Resources plc (formerly URA Resources plc) on London Stock Exchange Main Market IPO.
  • Hamak Strategy Limited (formerly Hamak Gold Limited) on London Stock Exchange Main Market IPO.
  • Heptares Therapeutics Limited, as a major shareholder, on Centessa Pharmaceuticals plc Nasdaq IPO.
  • Hummingbird Ventures Limited, as a major shareholder, on Deliveroo plc London Stock Exchange Main Market IPO.
  • Kistos Holdings plc on AIM direct listing.
  • Mercantile Ports & Logistics Limited on AIM follow-on offerings.
  • National World plc on London Stock Exchange Main Market SPAC IPO.
  • Nxera Pharma Co. Ltd (formerly Sosei Group Corporation) on acquisition of equity stake in Swiss SIX-listed Santhera Pharmaceuticals AG.
  • Nightstar Therapeutics plc on Nasdaq IPO.
  • OKYO Pharma Limited on London Stock Exchange Main Market IPO, Nasdaq dual-listing, subsequent Main Market delisting, and global follow-on offerings.
  • One Media IP Group plc on AIM follow-on offerings.
  • Panther Metals plc on London Stock Exchange Main Market follow-on offerings.
  • Realm Therapeutics plc on direct Nasdaq dual-listing and subsequent voluntary delisting from AIM.
  • RegTech Open Project plc on London Stock Exchange Main Market direct listing.
  • Renalytix plc on corporate demerger, AIM IPO, and Nasdaq dual-listing.
  • "Romgaz" S.A. on London Stock Exchange Main Market IPO.
  • Scancell Holdings plc on AIM follow-on offerings.
  • Supply@ME Capital plc on London Stock Exchange Main Market follow-on offerings.
  • TCS Group Holdings plc (Tinkoff Credit Systems) on London Stock Exchange Main Market IPO.
  • Tiziana Life Sciences Limited on cross-border corporate reorganisation, including transfer of listing from AIM to London Stock Exchange Main Market, Nasdaq dual-listing, Main Market delisting, Bermudan re-domiciliation, establishment of At-The-Market (ATM) facility, brokered offerings, and registered direct offerings.
  • VEF AB on transfer of listing from the Nasdaq First North exchange to the Nasdaq Stockholm Main Market.
  • Zamaz plc on London Stock Exchange Main Market direct listing and concurrent Private Investment in Public Equity (PIPE) transaction.

  Acting for investment banks:

  • The financial adviser on London Stock Exchange Main Market IPO of "MORE" preferred shares by The Smarter Web Company plc.
  • The underwriters on London Stock Exchange Main Market follow-on offering by Nuformix plc.
  • The joint bookrunners on London Stock Exchange Main Market convertible loan note financing by Hawkwing plc.
  • The underwriters on London Stock Exchange Main Market IPOs of Auto Trader Group plc, Exova Group plc, and Glencore plc.
  • The underwriters on London Stock Exchange Main Market direct listing of Metro Bank plc.
  • The underwriters on Nasdaq IPOs and follow-on offerings of Bicycle Therapeutics plc, Compass Pathways plc, and NuCana plc, alongside the proposed Nasdaq IPOs of Horizon Discovery plc, Kymab Limited, Mereo BioPharma Group plc, and Verona Pharma plc.

  Public & Private M&A

  • Kistos plc on proposed public offer for Serica Energy plc.
  • Kistos Holdings plc on cross-border acquisition of Mime Petroleum A.S.
  • Mindflair plc (formerly Pires Investments plc) on recommended public takeover by Tern plc.
  • MightyHive Inc. on acquisition by S4 Capital plc.
  • National World plc on proposed public offer for Reach plc.
  • National World plc on recommended cash acquisition by Media Concierge (Holdings) Limited.
  • National World plc on strategic bidding and auction process for The Telegraph Media Group.
  • Nxera Pharma on cross-border acquisition of Idorsia S.A.’s pharmaceuticals business in Japan and the APAC region (excluding China).
  • Realm Therapeutics plc on recommended Nasdaq public takeover by Essa Pharma Inc.
  • Stubben Edge Group Limited on corporate acquisition of Jaywing UK Limited.

  De-SPAC Business Combinations, RTOs & Reverse Mergers

  • Atlas Metals Group plc on proposed reverse takeover of Compagnie Minière de Oumejrane on the London Stock Exchange Main Market.
  • Crown PropTech Acquisitions on NYSE de-SPAC business combination with Mkango.
  • Cy Biopharma, Inc. on Nasdaq reverse merger with Ensysce Biosciences, Inc. and associated private placement financing.
  • Kinnevik AB on NYSE de-SPAC business combination of Babylon Health Limited with Alkuri Global Acquisition Corp., including the concurrent PIPE financing.
  • Kistos plc on AIM reverse takeover of Tulip Oil Netherlands B.V.
  • National World plc on London Stock Exchange Main Market reverse takeover of JPI Media.
  • RockRose Energy plc on London Stock Exchange Main Market reverse takeovers of North Sea energy assets acquired from Marathon Oil UK and Idemitsu Petroleum.
  • Shard Credit Partners Limited, as a major shareholder, on AIM reverse takeover of Sorted Holdings Limited by Location Sciences Group plc.
  • Technologies New Energy plc on London Stock Exchange Main Market de-SPAC business combination with Technologies New Energy S.A.
  • Tooru plc on AIM reverse takeover of certain operating subsidiaries of S-Venture plc.
  • VNV Global AB on Nasdaq de-SPAC business combinations of Swvl with Queen's Gambit Growth Capital, and Gett with Rosecliff Acquisition Corp I.

  Venture Capital & Private Capital Financings

  • A family office on seed financing round for a UK-based fintech enterprise.
  • A fintech enterprise on Series A extension and concurrent convertible loan note financing.
  • FOMTECH Limited (Floww) on Series B and Series C venture capital financings.
  • Metro Africa Xpress Inc. (MAX.ng) on Series B growth equity financing.
  • MyEdSpace Ltd on Series A venture capital financing.

  Strategic Advisory & Corporate Governance

  • capAI plc on strategic alliance agreement with R42 Group, Inc.
  • Floww on strategic partnership with London Stock Exchange Group (LSEG) to establish a global private capital market network.
  • Force Over Mass Capital LLP on complex general partnership and LLP structural matters.
  • Nxera Pharma on global collaboration and strategic licensing agreements with Neurocrine Biosciences Inc., Eli Lilly and Co., Santhera Pharmaceuticals AG, Viatris Inc., and an undisclosed global biomedical corporation.
  • Round Group Limited on establishment of Apex influencer and digital creator business ecosystem.